RASTETTER WILLIAM H 4

What Happened

• William H. Rastetter, a non-employee director of Fate Therapeutics (FATE), was granted a derivative award covering 87,900 shares on June 12, 2026. The reported price for the grant is $0.00 and the transaction is recorded as a derivative award (code A) — no cash was paid at grant.

Key Details

• Transaction date: 2026-06-12; Form 4 filed: 2026-06-15.
• Instrument: Derivative award (options/award) for 87,900 shares; reported price $0.00.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes: F1 — grant made under the Issuer’s Amended and Restated Non‑Employee Director Compensation Policy (annual director equity grant at the annual meeting). F2 — the shares subject to the option vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the Issuer’s 2027 Annual Meeting, conditioned on continued board service.
• Filing timeliness: Form 4 reports the transaction three days later (filed 6/15 for a 6/12 grant); the filing itself shows the report date but does not include a late‑filing note in the provided data.

Context

• This is an annual equity grant to a non-employee director under the company’s director compensation policy, not a purchase or sale. Such grants are routine compensation and do not by themselves indicate the director bought or sold shares in the open market. The award vests over roughly one year subject to continued service per the footnote.